RESULT_COUNT: 204,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
BGNE,BGNE:UW,BBG00B6WF8G7,China biotech's 'coming out party' masks long road ahead,2017-10-19 06:03:58 +0000,https://finance.yahoo.com/news/china-biotechs-coming-party-masks-060358110.html?.tsrc=rss,"LONDON/SHANGHAI (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West.  Shares in firms such as Chi-Med (HCM.L), Beigene (BGNE.O)  and Zai Lab (ZLAB.O) have soared on international markets this year, fuelled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals.  ""It's almost a coming out party for China biotech,"" said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (AZN.L)."
BGNE,BGNE:UW,BBG00B6WF8G7,"Tuesday's ETF Movers: IHF, GXC",2017-10-17 18:51:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9mpj1XoKEeM/tuesdays-etf-movers-ihf-gxc-cm860890,In trading on Tuesday the iShares U S Healthcare Providers ETF IHF is outperforming other ETFs up about 1 5 on the day Components of that ETF showing particular strength include shares of UnitedHealth Group UNH up about 5 3 and shares of Teladoc TDOC up about 2 9 on the
BGNE,BGNE:UW,BBG00B6WF8G7,"INFI Turns Heads, ARDX Marches On, VYGR Cruises Ahead, ACRX Disappoints",2017-10-12 22:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FEwi-tOveCk/infi-turns-heads-ardx-marches-on-vygr-cruises-ahead-acrx-disappoints-20171012-01452,"INFI Turns Heads, ARDX Marches On, VYGR Cruises Ahead, ACRX Disappoints"
BGNE,BGNE:UW,BBG00B6WF8G7,"BGNE Hits Record High, SYRS Awaits Catalysts, ALT To Report Data In Q4",2017-10-09 21:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6GlMZ2lj2pU/bgne-hits-record-high-syrs-awaits-catalysts-alt-to-report-data-in-q4-20171009-01000,"BGNE Hits Record High, SYRS Awaits Catalysts, ALT To Report Data In Q4"
BGNE,BGNE:UW,BBG00B6WF8G7,Strange: Bullish BGNE Analysts Actually See -14.29% Downside,2017-10-09 14:53:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rOF5XuL6e5Y/strange-bullish-bgne-analysts-actually-see-1429-downside-cm856926,Analyst ratings can sometimes be complicated and we here at ETF Channel have noticed a bit of a paradox with BeiGene Ltd Symbol BGNE The average 12 month price target for BGNE averaging the work of 4 analysts reveals an average price target of 89 00 share That s a whopping 14 29
BGNE,BGNE:UW,BBG00B6WF8G7,"[$$] Celgene Invests in Acceleron, BeiGene",2017-09-29 09:50:00 +0000,http://finance.yahoo.com/r/b007c187-ee13-3f28-8486-27ab1e401ec2/celgene-investments-in-acceleron-beigene-1506678656?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Celgene doesn’t let a partner down.  The biotech on Monday bought 750,000 more shares of Acceleron (XLRN) for $28 million in a public stock offering.  Celgene (CELG) remains Acceleron’s largest holder and is a partner for the latter’s lead program, Luspatercept, and for sotatercept."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO,2017-09-28 13:00:00 +0000,https://finance.yahoo.com/news/beigene-presents-preliminary-phase-1-130000946.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, Sept. 28, 2017-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"Gainers & Losers Of Sep.27: ADXS, BGNE, CDXS, VSAR, ITCI...",2017-09-28 00:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b3dOVTHGDqo/gainers--losers-of-sep27-adxs-bgne-cdxs-vsar-itci-20170928-00002,"Gainers & Losers Of Sep.27: ADXS, BGNE, CDXS, VSAR, ITCI..."
BGNE,BGNE:UW,BBG00B6WF8G7,This Biotech Makes Bold Move On Potential For Speedier Drug OK,2017-09-27 20:42:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/twJ5s9UhWhM/this-biotech-makes-bold-move-on-potential-for-speedier-drug-ok-cm852095,Audentes Therapeutics BOLD stock made a bold move Wednesday after the Food and Drug Administration granted one of its drugs a so called fast track designation but it gave back much of its gains as the trading day wore on ibd display video id 2322998 width 50 float
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology,2017-09-21 20:15:00 +0000,https://finance.yahoo.com/news/beigene-announces-presentation-20th-annual-201500899.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, Sept. 21, 2017-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ..."
BGNE,BGNE:UW,BBG00B6WF8G7,These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?,2017-09-19 13:38:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k_oVn29DKgI/these-3-biotech-stocks-just-hit-52-week-highs-are-they-buys-cm847598,These are the best times in a long time for three small biotechs For two of them these are the best times ever Abeona Therapeutics NASDAQ ABEO BeiGene NASDAQ BGNE and Vanda Pharmaceuticals NASDAQ VNDA stocks recently hit 52 week highs Abeona and BeiGene
BGNE,BGNE:UW,BBG00B6WF8G7,These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?,2017-09-19 11:31:00 +0000,http://finance.yahoo.com/r/1f246f85-650d-334f-a43a-90fc13ec017d/these-3-biotech-stocks-just-hit-52-week-highs-ar-2.aspx?yptr=yahoo&.tsrc=rss,"Will the good times keep rolling for Abeona Therapeutics, BeiGene, and Vanda Pharmaceuticals?"
BGNE,BGNE:UW,BBG00B6WF8G7,[$$] Celgene Launch to Lift BeiGene,2017-09-12 17:34:00 +0000,http://finance.yahoo.com/r/e25e1396-0569-3a15-82cf-e5c3e01a576c/celgene-launch-to-lift-beigene-1505237681?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"BeiGene (BGNE: Nasdaq) By Maxim Group ($72.64, Sept. 8, 2017) We have updated our BeiGene model to include the launch of BGB-A317 in the U.S. by Celgene, following the close of the transaction. Our model ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress,2017-09-11 07:00:00 +0000,https://finance.yahoo.com/news/beigene-presents-preliminary-phase-1-070000154.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, Sept. 11, 2017-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress,2017-09-08 10:00:00 +0000,https://finance.yahoo.com/news/beigene-presents-preliminary-phase-1-100000028.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, Sept. 08, 2017-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BGNE Crosses Above Average Analyst Target,2017-09-07 14:50:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8dy-5dTGlTs/bgne-crosses-above-average-analyst-target-cm842165,In recent trading shares of BeiGene Ltd Symbol BGNE have crossed above the average analyst 12 month target price of 75 25 changing hands for 76 66 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation or re
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Closing of Global Strategic Oncology Collaboration with Celgene Corporation,2017-08-31 20:05:00 +0000,https://finance.yahoo.com/news/beigene-announces-closing-global-strategic-200500048.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, Aug. 31, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Presentations at the European Society for Medical Oncology 2017 Congress,2017-08-30 22:05:00 +0000,https://finance.yahoo.com/news/beigene-announces-presentations-european-society-220500179.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, Aug. 30, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Present at Upcoming Investor Conferences,2017-08-30 20:15:00 +0000,https://finance.yahoo.com/news/beigene-present-upcoming-investor-conferences-201500189.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, Aug. 30, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Lower in Monday Trading,2017-08-28 14:49:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q37cKNtwxgQ/asian-adrs-move-lower-in-monday-trading-cm837932,American depositary receipts of Asian stocks were trading 0 34 lower at 168 16 on the Bank of New York Mellon Asia ADR Index on Monday American depositary receipts of Asian stocks were trading 0 34 lower at 168 16 on the Bank of New York Mellon Asia ADR Index on Monday In North Asia the
BGNE,BGNE:UW,BBG00B6WF8G7,Why I Love Celgene Corporation,2017-08-15 13:37:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nqinhxAJ6js/why-i-love-celgene-corporation-cm832052,Stocks aren t like children It s not a problem at all if you don t love each stock in your investment portfolio equally You can have favorites without even the smallest amount of guilt In my case Celgene Corporation NASDAQ CELG stands out among all the stocks that I own It
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Pricing of $175 Million Public Offering,2017-08-11 02:14:00 +0000,https://finance.yahoo.com/news/beigene-announces-pricing-175-million-021400250.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, Aug. 10, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Proposed Public Offering,2017-08-09 20:11:00 +0000,https://finance.yahoo.com/news/beigene-announces-proposed-public-offering-201100913.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, Aug. 09, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Reports Second Quarter 2017 Financial Results,2017-08-09 20:01:00 +0000,https://finance.yahoo.com/news/beigene-reports-second-quarter-2017-200100546.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,How Celgene Performed in 2Q17,2017-08-09 18:36:00 +0000,http://finance.yahoo.com/r/4590d37d-74d8-37e8-96cf-f78c29b8283f/celgene-performed-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Celgene updated its adjusted diluted EPS from $7.15–$7.30 to $7.25–$7.35 and its adjusted operating margin from about 57.0%–57.5%.
BGNE,BGNE:UW,BBG00B6WF8G7,Why BeiGene Soared 56.6% In July,2017-08-09 13:37:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7u-8spsdnHo/why-beigene-soared-566-in-july-cm829254,What happened After inking a collaboration agreement with biotech powerhouse Celgene NASDAQ CELG shares in BeiGene Ltd NASDAQ BGNE rocketed 56 6 higher last month 160 according to S amp P Global Market Intelligence So what Celgene
BGNE,BGNE:UW,BBG00B6WF8G7,Why BeiGene Soared 56.6% In July,2017-08-09 12:01:00 +0000,http://finance.yahoo.com/r/fda31e6c-d12c-3c17-82a0-5dd7e141510a/why-beigene-soared-566-in-july.aspx?yptr=yahoo&.tsrc=rss,The company inked a trans-formative deal with biotech behemoth Celgene last month.
BGNE,BGNE:UW,BBG00B6WF8G7,BGNE Crosses Above Average Analyst Target,2017-08-04 15:02:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XeN0ZPh_fHM/bgne-crosses-above-average-analyst-target-cm827281,In recent trading shares of BeiGene Ltd Symbol BGNE have crossed above the average analyst 12 month target price of 71 33 changing hands for 71 61 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation or re
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Lower in Thursday Trading,2017-08-03 14:39:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6nw0BL-eO_0/asian-adrs-move-lower-in-thursday-trading-cm826466,American depository receipts of Asian stocks were trading 0 20 lower at 167 86 on the Bank of New York Mellon Asia ADR Index on Thursday American depository receipts of Asian stocks were trading 0 20 lower at 167 86 on the Bank of New York Mellon Asia ADR Index on Thursday In North Asia
BGNE,BGNE:UW,BBG00B6WF8G7,These 3 Stocks Have Doubled Investors' Money in 2017,2017-07-17 11:48:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zlHkZEQmGn0/these-3-stocks-have-doubled-investors-money-in-2017-cm816670,The stock market has done well so far in 2017 with gains of almost 10 for the S amp P 500 and even greater rises for some other major market benchmarks A small number of top performing stocks have done a lot better than that with a select handful having managed to double
BGNE,BGNE:UW,BBG00B6WF8G7,These 3 Stocks Have Doubled Investors&apos; Money in 2017,2017-07-17 10:06:00 +0000,http://finance.yahoo.com/r/d9ddf51e-4ac4-3bfd-a8a6-c2cc28c2a666/these-3-stocks-have-doubled-investors-money-in-201.aspx?yptr=yahoo&.tsrc=rss,Find out how these stocks have jumped so much this year.
BGNE,BGNE:UW,BBG00B6WF8G7,"Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal",2017-07-12 13:39:01 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-arena-shoots-133901394.html?.tsrc=rss,Arena (ARNA) saw it shares shoot up on mid-stage data on its pulmonary arterial hypertension drug while quite a few companies provided regulatory updates.
BGNE,BGNE:UW,BBG00B6WF8G7,[$$] BeiGene Boosted by Celgene Deal,2017-07-10 15:32:00 +0000,http://finance.yahoo.com/r/9ddff3a1-7d43-3151-86c3-fdba74bd2d26/beigene-boosted-by-celgene-deal-1499700771?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Maxim Group  We believe BeiGene has landed a solid deal with an excellent oncology partner in Celgene.  On the global front, it is strategic for BeiGene (BGNE) to expand the development of BGB-A317 in multiple indications with a partner, it also mitigates the risk of developing and commercializing its PD-1 inhibitor by itself in a highly competitive space.  The acquisition of Celgene’s (CELG) China business brings immediate revenues to BeiGene and more importantly, the existing commercial infrastructure sets the stage for commercial launches following the approvals on pivotal studies of BGB-A317 and BGB-3111 in China."
BGNE,BGNE:UW,BBG00B6WF8G7,Why Celgene&apos;s $413 Million Gamble Helps This Small Biotech More,2017-07-07 20:42:28 +0000,http://finance.yahoo.com/r/904f729d-e57e-3367-b8fe-76eb17a7ebc5/why-celgenes-413-million-gamble-helps-this-small-biotech-more?src=A00220&yptr=yahoo&.tsrc=rss,"Chinese biotech BeiGene is the strongest beneficiary of Celgene&apos;s $413 million gamble in immuno-oncology, an analyst said Friday."
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Lower in Friday Trading,2017-07-07 15:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lMW-KsXSaz4/asian-adrs-move-lower-in-friday-trading-cm813052,American depository receipts of Asian stocks were trading 0 13 lower at 158 89 on the Bank of New York Mellon Asia ADR Index on Friday American depository receipts of Asian stocks were trading 0 13 lower at 158 89 on the Bank of New York Mellon Asia ADR Index on Friday In North Asia the
BGNE,BGNE:UW,BBG00B6WF8G7,"Celgene (CELG), BeiGene Team Up For PD-1 Inhibitor in China",2017-07-06 22:45:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/39s_HzG0JKw/celgene-celg-beigene-team-up-for-pd-1-inhibitor-in-china-cm812738,Celgene Corporation CELG recently entered into a strategic collaboration with China based BeiGene Ltd BGNE Per the deal Celgene will develop and commercialize BeiGene s investigational anti programmed cell death protein 1 PD 1 inhibitor BGB A317 The candidate will be used to
BGNE,BGNE:UW,BBG00B6WF8G7,"Gainers & Losers Of July 6: VSTM, BGNE, ALRN, TXMD, OCUL...",2017-07-06 21:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GwZFFCJZQoc/gainers--losers-of-july-6-vstm-bgne-alrn-txmd-ocul-20170706-01273,"Gainers & Losers Of July 6: VSTM, BGNE, ALRN, TXMD, OCUL..."
BGNE,BGNE:UW,BBG00B6WF8G7,"Why HSN, Herman Miller, and BeiGene Jumped Today",2017-07-06 21:44:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3b47PeAz9jw/why-hsn-herman-miller-and-beigene-jumped-today-cm812698,The stock market lost ground on Thursday with major benchmarks falling around 1 on the day Rising tensions on the geopolitical front weighed on sentiment especially because of the North Korean test launch of an intercontinental ballistic missile and the attendant threat that it poses
BGNE,BGNE:UW,BBG00B6WF8G7,"Celgene (CELG), BeiGene Team Up For PD-1 Inhibitor in China",2017-07-06 20:52:08 +0000,https://finance.yahoo.com/news/celgene-celg-beigene-team-pd-205208539.html?.tsrc=rss,"Celgene Corporation (CELG) recently entered into a strategic collaboration with China based-BeiGene, Ltd. (BGNE)."
BGNE,BGNE:UW,BBG00B6WF8G7,Celgene Enters PD1 Market with BeiGene Deal,2017-07-06 20:42:00 +0000,http://finance.yahoo.com/r/82635255-33b9-3824-b4bf-43338eb5af8e/celgene-enters-pd1-market-with-beigene-deal.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research."
BGNE,BGNE:UW,BBG00B6WF8G7,"Why HSN, Herman Miller, and BeiGene Jumped Today",2017-07-06 20:28:00 +0000,http://finance.yahoo.com/r/21b33f4f-dbdb-3097-bb2f-0e220f2efded/why-hsn-herman-miller-and-beigene-jumped-today.aspx?yptr=yahoo&.tsrc=rss,These stocks gained in a tough market. Find out why.
BGNE,BGNE:UW,BBG00B6WF8G7,"Health Care Sector Update for 07/06/2017: CORI,BGNE,CELG,EGLT",2017-07-06 20:23:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gePKlnyNOdQ/health-care-sector-update-for-07062017-coribgnecelgeglt-cm812688,Top Health Care StocksTop Health Care Stocks JNJ 0 87 JNJ 0 87 PFE 0 64 PFE 0 64 ABT 1 29 ABT 1 29 MRK 1 20 MRK 1 20 AMGN 1 44 AMGN 1 44 Health care stocks were leading the U S markets lower today with the NYSE Health Care Index on a 0 9 slide this afternoon while shares of
BGNE,BGNE:UW,BBG00B6WF8G7,Here's Why BeiGene Ltd. Rose as Much as 31.4% on Thursday,2017-07-06 19:45:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KeDN4Mkleeo/heres-why-beigene-ltd-rose-as-much-as-314-on-thursday-cm812634,What happened Shares of BeiGene Ltd NASDAQ BGNE rocketed more than 31 higher at one point Thursday morning after the 160 clinical stage biopharma announced a new collaboration with Celgene Corp NASDAQ CELG The biopharma giant acquired worldwide rights outside
BGNE,BGNE:UW,BBG00B6WF8G7,"Health Care Sector Update for 07/06/2017: IMGN,BGNE,CELG,EGLT",2017-07-06 18:23:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-AM9Dl9OBSE/health-care-sector-update-for-07062017-imgnbgnecelgeglt-cm812622,Top Health Care StocksTop Health Care Stocks JNJ 0 87 JNJ 0 87 PFE 0 64 PFE 0 64 ABT 1 29 ABT 1 29 MRK 1 20 MRK 1 20 AMGN 1 44 AMGN 1 44 Health care stocks were leading the U S markets lower with the NYSE Health Care Index on a 0 9 slide this afternoon while shares of health
BGNE,BGNE:UW,BBG00B6WF8G7,Here&apos;s Why BeiGene Ltd. Rose as Much as 31.4% on Thursday,2017-07-06 18:07:00 +0000,http://finance.yahoo.com/r/c7d18b09-2251-3218-bf5b-c2174acdb0e7/heres-why-beigene-ltd-rose-as-much-as-31-thursday.aspx?yptr=yahoo&.tsrc=rss,The mid-cap Chinese biopharma announced a collaboration with Celgene that has a few interesting twists to it.
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Lower in Thursday Trading,2017-07-06 17:24:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iDKy8rw2B6c/asian-adrs-move-lower-in-thursday-trading-cm812582,American depository receipts of Asian stocks were trading 0 70 lower at 159 64 on the Bank of New York Mellon Asia ADR Index on Thursday American depository receipts of Asian stocks were trading 0 70 lower at 159 64 on the Bank of New York Mellon Asia ADR Index on Thursday In North Asia
BGNE,BGNE:UW,BBG00B6WF8G7,Celgene signs deal with BeiGene for tumor cancer treatment,2017-07-06 16:21:06 +0000,https://finance.yahoo.com/news/celgene-signs-deal-beigene-tumor-162106555.html?.tsrc=rss,"Celgene Corp said it would buy a  stake in BeiGene Ltd to help develop and commercialize  the China-based cancer immunotherapy developer's treatment for  solid tumor cancers, expanding its position in the field of  immuno-oncology.  BeiGene's shares rose as much as 31.4 percent to an all-time  high of $68.67 in afternoon trading on Thursday.  Celgene's  shares were marginally down."
BGNE,BGNE:UW,BBG00B6WF8G7,Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring,2017-07-06 13:29:00 +0000,http://finance.yahoo.com/r/18d26f66-5b69-31c0-b7f3-3377c5b9aa22/biotech-movers-immuno-oncology-pact-with-celgene-sends-beigene-shares-soaring.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,BeiGene and Impax Laboratories were among the biotech movers in premarket trading on July 6.
BGNE,BGNE:UW,BBG00B6WF8G7,How Transformative Is This Licensing Deal for BeiGene?,2017-07-06 12:35:09 +0000,https://finance.yahoo.com/news/transformative-licensing-deal-beigene-123509897.html?.tsrc=rss,"This partnership should be fairly transformative for BeiGene, seeing as it can start making some actual money."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene stock surges 12% on Celgene cancer collaboration,2017-07-06 12:27:47 +0000,http://finance.yahoo.com/r/7b6805d5-1994-38c4-aa8f-19af7e55a40a/Story.aspx?guid=4617CA21-96B2-4703-8BD6-F2B04A270E3C&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"BeiGene Ltd. shares surged 12.6% in premarket trade Thursday on news of its cancer collaboration with Celgene Corp. . BeiGene will receive $263 million in upfront licensing fees, and is eligible for up ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"US STOCKS-Futures lower ahead of trade, ADP jobs data",2017-07-06 11:30:45 +0000,https://finance.yahoo.com/news/us-stocks-futures-lower-ahead-113045992.html?.tsrc=rss,"U.S. stock index futures were lower on  Thursday ahead of data on trade and private sector hiring, a day  after the Federal Reserve's policy minutes failed to provide a  clear picture of future interest rate increases.  * Fed policymakers were increasingly split on the outlook  for inflation and how it might affect the future pace of  interest rate hikes, according to minutes of the Fed's last  policy meeting released on Wednesday.  * The Fed's preferred measure of underlying inflation  slipped to 1.4 percent in May and has run below the 2 percent  target for more than five years now."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Ltd. (BGNE) Has Climbed To A New High On Celgene Deal,2017-07-06 09:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xH5s1Mf_iXs/beigene-ltd-bgne-has-climbed-to-a-new-high-on-celgene-deal-20170706-00688,BeiGene Ltd. (BGNE) Has Climbed To A New High On Celgene Deal
BGNE,BGNE:UW,BBG00B6WF8G7,"ARRY Working Its Way, Be All Ears For Auris, BGNE Inks Deal With CELG",2017-07-06 04:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S1i7ltsXB9E/arry-working-its-way-be-all-ears-for-auris-bgne-inks-deal-with-celg-20170706-00114,"ARRY Working Its Way, Be All Ears For Auris, BGNE Inks Deal With CELG"
BGNE,BGNE:UW,BBG00B6WF8G7,"Celgene to buy BeiGene stake, to develop tumor cancer treatment",2017-07-06 02:05:49 +0000,https://finance.yahoo.com/news/celgene-buy-beigene-stake-develop-020549094.html?.tsrc=rss,"Biopharmaceutical company Celgene Corp  will buy a stake in BeiGene Ltd and help  develop and commercialize BeiGene's investigational treatment  for tumor cancers, the companies said on Wednesday.  Celgene will acquire 32.7 million, or 5.9 percent of  BeiGene's ordinary shares, at $4.58 each, or $59.55 per  BeiGene's American Depositary Shares (ADS), they said in a  statement."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Host Investor Conference Call on Global Strategic Collaboration with Celgene,2017-07-06 01:15:00 +0000,https://finance.yahoo.com/news/beigene-host-investor-conference-call-011500312.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, July 05, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers,2017-07-06 01:00:00 +0000,https://finance.yahoo.com/news/celgene-corporation-enters-global-strategic-010000354.html?.tsrc=rss,"Celgene Corporation and BeiGene, Ltd. entered into a strategic collaboration to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317, for patients with solid tumor cancers in the United States, Europe, Japan and rest of world outside Asia."
BGNE,BGNE:UW,BBG00B6WF8G7,"Celgene, BeiGene Collaborate On PD-1 Inhibitor Program For Solid Tumor Cancers",2017-07-05 22:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o18w3DrRGI4/celgene-beigene-collaborate-on-pd1-inhibitor-program-for-solid-tumor-cancers-20170705-01204,"Celgene, BeiGene Collaborate On PD-1 Inhibitor Program For Solid Tumor Cancers"
BGNE,BGNE:UW,BBG00B6WF8G7,"Health Care Sector Update for 07/05/2017: ATNX,MTBC,BGNE",2017-07-05 20:23:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J9f8g1WeOfk/health-care-sector-update-for-07052017-atnxmtbcbgne-cm812083,Top Health Care StocksTop Health Care Stocks JNJ 0 58 JNJ 0 58 PFE 0 64 PFE 0 64 ABT 0 63 ABT 0 63 MRK 0 25 MRK 0 25 AMGN 0 64 AMGN 0 64 Health care stocks built on moderate gains earlier today with the NYSE Health Care Index climbing about 0 3 while shares of health care
BGNE,BGNE:UW,BBG00B6WF8G7,"Health Care Sector Update for 07/05/2017: NVRO,MTBC,BGNE",2017-07-05 18:23:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xw84EK0yhBo/health-care-sector-update-for-07052017-nvromtbcbgne-cm812016,Top Health Care StocksTop Health Care Stocks JNJ 0 43 JNJ 0 43 PFE 0 65 PFE 0 65 ABT 0 56 ABT 0 56 MRK 0 36 MRK 0 36 AMGN 0 53 AMGN 0 53 Health care stocks were holding moderate gains with the NYSE Health Care Index climbing about 0 1 while shares of health care companies in
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene (BGNE) Surges: Stock Moves 20.8% Higher,2017-07-05 14:50:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EJzvcIpbsYQ/beigene-bgne-surges-stock-moves-208-higher-cm811780,BeiGene Ltd BGNE was a big mover last session as the company saw its shares rise almost 21 on Monday The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above the
BGNE,BGNE:UW,BBG00B6WF8G7,This Biotech Stock Is Surging More Than 20% Today,2017-07-05 14:37:00 +0000,http://finance.yahoo.com/r/8ed92ae6-eed5-385f-8cbf-6fa27519f6a9/biotech-movers-celsion-array-beigene.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Here are the names.
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene (BGNE) Surges: Stock Moves 20.8% Higher,2017-07-05 12:33:12 +0000,https://finance.yahoo.com/news/beigene-bgne-surges-stock-moves-123312635.html?.tsrc=rss,"BeiGene (BGNE) was a big mover last session, as the company saw its shares rise almost 21% on Monday amid huge volumes."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Initiates Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer,2017-07-05 11:00:00 +0000,https://finance.yahoo.com/news/beigene-initiates-pivotal-trial-pd-110000594.html?.tsrc=rss,"BEIJING, China, and CAMBRIDGE, Mass., July 05, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly targeted and immuno-oncology drugs for the treatment of cancer, today ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Higher in Monday Trading,2017-07-03 15:43:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Uf9AqT0uNpk/asian-adrs-move-higher-in-monday-trading-cm811258,American depository receipts of Asian stocks were trading 0 55 higher at 160 16 on the Bank of New York Mellon Asia ADR Index on Monday American depository receipts of Asian stocks were trading 0 55 higher at 160 16 on the Bank of New York Mellon Asia ADR Index on Monday In North Asia
BGNE,BGNE:UW,BBG00B6WF8G7,InPlay from Briefing.com,2017-06-29 09:56:08 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Preliminary Phase 1 Data on BGB-A317 in Patients with Hepatocellular Carcinoma at the ESMO 19th World Congress on Gastrointestinal Cancer,2017-06-29 09:10:00 +0000,https://finance.yahoo.com/news/beigene-presents-preliminary-phase-1-091000573.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, June 29, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 14th International Conference on Malignant Lymphoma and Announces Additional Planned Global Registrational Trials for BGB-3111,2017-06-16 09:50:00 +0000,https://finance.yahoo.com/news/beigene-presents-initial-phase-1-095000542.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, June 16, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 14th International Conference on Malignant Lymphoma,2017-06-15 14:00:00 +0000,https://finance.yahoo.com/news/beigene-presents-updated-phase-1-140000541.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, June 15, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant Lymphoma,2017-06-14 10:00:00 +0000,https://finance.yahoo.com/news/beigene-presents-updated-phase-1-100000338.html?.tsrc=rss,"CAMBRIDGE, Mass. and BEIJING, China, June 14, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Present at Upcoming Investor Conferences,2017-06-07 20:15:00 +0000,https://finance.yahoo.com/news/beigene-present-upcoming-investor-conferences-201500559.html?.tsrc=rss,"CAMBRIDGE, Mass., June 07, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference Call,2017-06-07 16:00:00 +0000,https://finance.yahoo.com/news/beigene-present-data-bgb-3111-160000622.html?.tsrc=rss,"CAMBRIDGE, Mass., June 07, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Lower in Monday Trading,2017-06-05 14:39:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l7apXf0VOqs/asian-adrs-move-lower-in-monday-trading-cm798662,American depositary receipts of Asian stocks were trading 0 48 lower at 158 58 on the Bank of New York Mellon Asia ADR Index on Monday American depositary receipts of Asian stocks were trading 0 48 lower at 158 58 on the Bank of New York Mellon Asia ADR Index on Monday In North Asia the
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting,2017-06-05 13:00:00 +0000,https://finance.yahoo.com/news/beigene-presents-initial-phase-1-130000715.html?.tsrc=rss,"CAMBRIDGE, Mass., June 05, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today presented ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Higher in Friday Trading,2017-06-02 15:31:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eFQR58GNTXU/asian-adrs-move-higher-in-friday-trading-cm798006,American depository receipts of Asian stocks were trading 0 55 higher at 158 67 on the Bank of New York Mellon Asia ADR Index on Friday American depository receipts of Asian stocks were trading 0 55 higher at 158 67 on the Bank of New York Mellon Asia ADR Index on Friday In North Asia
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Present at the 2017 UBS Global Healthcare Conference,2017-05-17 20:15:00 +0000,https://finance.yahoo.com/news/beigene-present-2017-ubs-global-201500326.html?.tsrc=rss,"CAMBRIDGE, Mass., May 17, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Reports First Quarter 2017 Financial Results,2017-05-10 20:15:00 +0000,http://finance.yahoo.com/news/beigene-reports-first-quarter-2017-201500221.html?.tsrc=rss,"CAMBRIDGE, Mass., May 10, 2017-- BeiGene, Ltd. a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today reported ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Higher in Thursday Trading,2017-04-27 14:45:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EuiuQi8ZokE/asian-adrs-move-higher-in-thursday-trading-cm780249,American depository receipts of Asian stocks were trading 0 20 higher at 154 70 on the Bank of New York Mellon Asia ADR Index on Thursday American depository receipts of Asian stocks were trading 0 20 higher at 154 70 on the Bank of New York Mellon Asia ADR Index on Thursday In North Asia
BGNE,BGNE:UW,BBG00B6WF8G7,"ETFs with exposure to BeiGene Ltd. : April 26, 2017",2017-04-26 19:08:23 +0000,http://finance.yahoo.com/r/f7eac6dc-6a5e-3d43-abe6-e0c56fa76c74/etfs-with-exposure-to-beigene-ltd-april-26-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BeiGene Ltd. Here are 5 ETFs with the largest exposure to BGNE-US. Comparing the performance and risk of BeiGene Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317,2017-04-21 11:00:00 +0000,http://finance.yahoo.com/news/beigene-announces-initiation-first-pivotal-110000305.html?.tsrc=rss,"BEIJING, April 21, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the first ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting,2017-04-21 11:00:00 +0000,http://finance.yahoo.com/news/beigene-announces-presentation-phase-study-110000365.html?.tsrc=rss,"CAMBRIDGE, Mass., April 21, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Myriad Genetics To Collaborate With BeiGene - Quick Facts,2017-04-06 07:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wMiyj8ZX60M/myriad-genetics-to-collaborate-with-beigene--quick-facts-20170406-00312,Myriad Genetics To Collaborate With BeiGene - Quick Facts
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2017-04-03 13:26:44 +0000,http://biz.yahoo.com/e/170403/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BGNE,BGNE:UW,BBG00B6WF8G7,3:29 am BeiGene reports Phase IB data on RAF dimer inhibitor BGB-283 demonstrating activity in both B-RAF and K-RAS-mutated tumors,2017-04-03 07:29:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#bgne,3:29 am BeiGene reports Phase IB data on RAF dimer inhibitor BGB-283 demonstrating activity in both B-RAF and K-RAS-mutated tumors
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting,2017-04-02 17:16:00 +0000,http://finance.yahoo.com/news/beigene-presents-phase-ib-data-171600212.html?.tsrc=rss,"CAMBRIDGE, Mass., April 02, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today presented ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting,2017-04-02 17:16:00 +0000,http://finance.yahoo.com/news/beigene-presents-phase-ib-data-171600212.html,"[GlobeNewswire] - CAMBRIDGE, Mass., April 02, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today presented ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Blog Coverage Agenus Announced Restructuring of Business,2017-03-31 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-agenus-announced-restructuring-121500958.html,"[Accesswire] - Upcoming AWS Coverage on BeiGene Post-Earnings Results LONDON, UK / ACCESSWIRE / March 31, 2017 / Active Wall St. blog coverage looks at the headline from Lexington based Agenus Inc. (NASDAQ: AGEN ) as ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Blog Coverage Agenus Announced Restructuring of Business,2017-03-31 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-agenus-announced-restructuring-121500958.html?.tsrc=rss,"Upcoming AWS Coverage on BeiGene Post-Earnings Results LONDON, UK / ACCESSWIRE / March 31, 2017 / Active Wall St. blog coverage looks at the headline from Lexington based Agenus Inc. (NASDAQ: AGEN ) as ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Financials",2017-03-28 17:04:07 +0000,http://finance.yahoo.com/q/is?s=bgne,"BEIGENE, LTD. Financials"
BGNE,BGNE:UW,BBG00B6WF8G7,"BeiGene Ltd. :BGNE-US: Earnings Analysis: 2016 By the Numbers : March 24, 2017",2017-03-24 14:16:34 +0000,http://www.capitalcube.com/blog/index.php/beigene-ltd-bgne-us-earnings-analysis-2016-by-the-numbers-march-24-2017/,"BeiGene Ltd. :BGNE-US: Earnings Analysis: 2016 By the Numbers : March 24, 2017"
BGNE,BGNE:UW,BBG00B6WF8G7,"BeiGene Ltd. :BGNE-US: Earnings Analysis: 2016 By the Numbers : March 24, 2017",2017-03-24 14:16:34 +0000,http://finance.yahoo.com/r/0d5fa3e5-a629-3849-ab4a-ab5e7b5812ca/beigene-ltd-bgne-us-earnings-analysis-2016-by-the-numbers-march-24-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis BeiGene Ltd. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of BeiGene Ltd. – OncoMed Pharmaceuticals, Inc., Omeros Corporation and Ohr Pharmaceutical, Inc. (OMED-US, OMER-US and OHRP-US) that have also reported for this period. Highlights Year-on-year change in operating cash ... Read more    
<b>(Read more...)</b>"
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits",2017-03-22 20:32:55 +0000,http://biz.yahoo.com/e/170322/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Reports Fourth Quarter and Full Year 2016 Financial Results,2017-03-22 20:15:00 +0000,http://finance.yahoo.com/news/beigene-reports-fourth-quarter-full-201500293.html,"[GlobeNewswire] - CAMBRIDGE, Mass., March 22, 2017-- BeiGene, Ltd. a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Reports Fourth Quarter and Full Year 2016 Financial Results,2017-03-22 20:15:00 +0000,http://finance.yahoo.com/news/beigene-reports-fourth-quarter-full-201500293.html?.tsrc=rss,"CAMBRIDGE, Mass., March 22, 2017-- BeiGene, Ltd. a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2017-03-09 21:22:34 +0000,http://biz.yahoo.com/e/170309/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLL,2017-03-09 21:15:00 +0000,http://finance.yahoo.com/news/beigene-announces-initiation-pivotal-study-211500938.html?.tsrc=rss,"BEIJING, March 09, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the dosing of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLL,2017-03-09 21:15:00 +0000,http://finance.yahoo.com/news/beigene-announces-initiation-pivotal-study-211500938.html,"[GlobeNewswire] - BEIJING, March 09, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the dosing of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati",2017-03-07 12:21:13 +0000,http://biz.yahoo.com/e/170307/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene and Guangzhou Development District Establish Joint Venture to Build Biologics Manufacturing Facility,2017-03-07 12:00:00 +0000,http://finance.yahoo.com/news/beigene-guangzhou-development-district-establish-120000763.html,"[GlobeNewswire] - State-of-the-Art Facility to Break Ground in 2017 Expected Direct Investments Total RMB2.2 Billion Funding Includes Support for Clinical Development in China. BEIJING and GUANGZHOU, China, March 07, 2017-- ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene and Guangzhou Development District Establish Joint Venture to Build Biologics Manufacturing Facility,2017-03-07 12:00:00 +0000,http://finance.yahoo.com/news/beigene-guangzhou-development-district-establish-120000763.html?.tsrc=rss,"State-of-the-Art Facility to Break Ground in 2017 Expected Direct Investments Total RMB2.2 Billion Funding Includes Support for Clinical Development in China. BEIJING and GUANGZHOU, China, March 07, 2017-- ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Presentation of Phase IB Data on BGB-283 at the 2017 American Association for Cancer Research Annual Meeting,2017-03-02 14:00:00 +0000,http://finance.yahoo.com/news/beigene-announces-presentation-phase-ib-140000849.html?.tsrc=rss,"CAMBRIDGE, Mass., March 02, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111,2017-03-02 14:00:00 +0000,http://finance.yahoo.com/news/beigene-announces-initiation-first-pivotal-140000683.html,"[GlobeNewswire] - BEIJING, March 02, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the dosing of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Presentation of Phase IB Data on BGB-283 at the 2017 American Association for Cancer Research Annual Meeting,2017-03-02 14:00:00 +0000,http://finance.yahoo.com/news/beigene-announces-presentation-phase-ib-140000849.html,"[GlobeNewswire] - CAMBRIDGE, Mass., March 02, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111,2017-03-02 14:00:00 +0000,http://finance.yahoo.com/news/beigene-announces-initiation-first-pivotal-140000683.html?.tsrc=rss,"BEIJING, March 02, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the dosing of ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Lower in Tuesday Trading,2017-02-28 15:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kQJCqW9mhc8/asian-adrs-move-lower-in-tuesday-trading-cm754189,American depository receipts of Asian stocks were trading 0 18 lower at 151 67 on the Bank of New York Mellon Asia ADR Index on Tuesday American depository receipts of Asian stocks were trading 0 18 lower at 151 67 on the Bank of New York Mellon Asia ADR Index on Tuesday In North Asia
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Present at the Cowen and Company 37th Annual Health Care Conference,2017-02-27 21:15:00 +0000,http://finance.yahoo.com/news/beigene-present-cowen-company-37th-211500990.html?.tsrc=rss,"CAMBRIDGE, Mass., Feb. 27, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Present at the Cowen and Company 37th Annual Health Care Conference,2017-02-27 21:15:00 +0000,http://finance.yahoo.com/news/beigene-present-cowen-company-37th-211500990.html,"[GlobeNewswire] - CAMBRIDGE, Mass., Feb. 27, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"Boxer Capital, LLC Buys AveXis, BeiGene, Alnylam Pharmaceuticals, Sells Biomarin ...",2017-02-17 20:51:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XwYgiiI0jBI/boxer-capital-llc-buys-avexis-beigene-alnylam-pharmaceuticals-sells-biomarin-cm749825,Boxer Capital LLC New Purchases ALNY ALXN SBBP SNSS BLPH RXDX Added Positions AVXS BGNE MDCO Reduced Positions SGEN CLVS ARDM Sold Out BMRN RIGL HRTX EBIO EPIX New Purchases ALNY ALXN SBBP SNSS BLPH RXDX
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference,2017-02-08 21:15:00 +0000,http://finance.yahoo.com/news/beigene-participate-leerink-partners-6th-211500054.html?.tsrc=rss,"CAMBRIDGE, Mass., Feb. 08, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference,2017-02-08 21:15:00 +0000,http://finance.yahoo.com/news/beigene-participate-leerink-partners-6th-211500054.html,"[GlobeNewswire] - CAMBRIDGE, Mass., Feb. 08, 2017-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,How The Pieces Add Up: FNI Targets $34,2017-02-01 15:32:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mjhidon1_bI/how-the-pieces-add-up-fni-targets-34-cm741461,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Higher in Friday Trading,2017-01-27 15:51:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HerumefdqA4/asian-adrs-move-higher-in-friday-trading-cm739329,American depository receipts of Asian stocks were trading 0 26 lower at 150 45 on the Bank of New York Mellon Asia ADR Index on Friday American depository receipts of Asian stocks were trading 0 26 lower at 150 45 on the Bank of New York Mellon Asia ADR Index on Friday In North Asia the
BGNE,BGNE:UW,BBG00B6WF8G7,Beigene Ltd (ADR) (BGNE): Here’s Our Take,2017-01-26 16:11:18 +0000,http://www.insidermonkey.com/blog/beigene-ltd-adr-bgne-heres-our-take-525583/,Beigene Ltd (ADR) (BGNE): Here’s Our Take
BGNE,BGNE:UW,BBG00B6WF8G7,Beigene Ltd (ADR) (BGNE): Here’s Our Take,2017-01-26 16:11:18 +0000,http://finance.yahoo.com/r/53dc1b70-7d82-3c7c-8658-52d2d0aea4c5/beigene-ltd-adr-bgne-heres-our-take-525583?yptr=yahoo&.tsrc=rss,"Beigene Ltd (ADR) (NASDAQ:BGNE) had a pretty tough time throughout the latter half of November and early to mid December. The company fell from November highs just ahead of $37 a share to below $27 a share in December – a more than 27% discount in a matter of weeks. Since the lows, however, Beigene has […]"
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2017-01-25 15:07:02 +0000,http://biz.yahoo.com/e/170125/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s Macroglobulinemia,2017-01-25 13:00:00 +0000,http://finance.yahoo.com/news/beigene-initiates-global-phase-iii-130000244.html?.tsrc=rss,"CAMBRIDGE, Mass., Jan. 25, 2017-- BeiGene, Ltd. a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s Macroglobulinemia,2017-01-25 13:00:00 +0000,http://finance.yahoo.com/news/beigene-initiates-global-phase-iii-130000244.html,"[GlobeNewswire] - CAMBRIDGE, Mass., Jan. 25, 2017-- BeiGene, Ltd. a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317,2016-12-30 15:12:07 +0000,http://www.publicnow.com/view/33F799BD1BC9C0E41D2BAE2B6BD3DDA05351C371,"[at noodls] - BEIJING, Dec. 30, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317,2016-12-30 14:00:00 +0000,http://finance.yahoo.com/news/beigene-announces-first-patient-dosing-140000733.html,"[GlobeNewswire] - BEIJING, Dec. 30, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the dosing of the ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290,2016-12-21 22:12:05 +0000,http://www.publicnow.com/view/F154218EF1F6264E397CA8CFA287F5E6E516DE65,"[at noodls] - BEIJING, Dec. 21, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Do Hedge Funds Love Nobilis Health Corp (USA) (HLTH)?,2016-12-16 12:53:12 +0000,http://finance.yahoo.com/r/b2e33930-f1ae-3ca9-8279-bd74c9252579/do-hedge-funds-love-nobilis-health-corp-usa-hlth-511230?yptr=yahoo&.tsrc=rss,"Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]"
BGNE,BGNE:UW,BBG00B6WF8G7,Do Hedge Funds Love Nobilis Health Corp (USA) (HLTH)?,2016-12-16 12:53:12 +0000,http://www.insidermonkey.com/blog/do-hedge-funds-love-nobilis-health-corp-usa-hlth-511230/,Do Hedge Funds Love Nobilis Health Corp (USA) (HLTH)?
BGNE,BGNE:UW,BBG00B6WF8G7,Should You Add Hawaiian Telcom HoldCo Inc (HCOM) to Your Portfolio?,2016-12-14 12:16:31 +0000,http://finance.yahoo.com/r/50693bad-ed3b-3d32-82de-2b57462f03f7/should-you-add-hawaiian-telcom-holdco-inc-hcom-to-your-portfolio-508999?yptr=yahoo&.tsrc=rss,"The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge funds have been producing disappointing net returns in recent years, however that was partly due to the poor performance of small-cap stocks in general. […]"
BGNE,BGNE:UW,BBG00B6WF8G7,Should You Add Hawaiian Telcom HoldCo Inc (HCOM) to Your Portfolio?,2016-12-14 12:16:31 +0000,http://www.insidermonkey.com/blog/should-you-add-hawaiian-telcom-holdco-inc-hcom-to-your-portfolio-508999/,Should You Add Hawaiian Telcom HoldCo Inc (HCOM) to Your Portfolio?
BGNE,BGNE:UW,BBG00B6WF8G7,Is Federated National Holding Co (FNHC) A Good Stock To Buy?,2016-12-14 11:12:22 +0000,http://finance.yahoo.com/r/9f073676-0e5e-3103-b222-35830b68a7e1/is-federated-national-holding-co-fnhc-a-good-stock-to-buy-508826?yptr=yahoo&.tsrc=rss,"We have been waiting for this for a year and finally the third quarter ended up showing a nice bump in the performance of small-cap stocks. Both the S&P 500 and Russell 2000 were up since the end of the second quarter, but small-cap stocks outperformed the large-cap stocks by double digits. This is important […]"
BGNE,BGNE:UW,BBG00B6WF8G7,Is Federated National Holding Co (FNHC) A Good Stock To Buy?,2016-12-14 11:12:22 +0000,http://www.insidermonkey.com/blog/is-federated-national-holding-co-fnhc-a-good-stock-to-buy-508826/,Is Federated National Holding Co (FNHC) A Good Stock To Buy?
BGNE,BGNE:UW,BBG00B6WF8G7,"BeiGene (BGNE): Strong Industry, Solid Earnings Estimate Revisions",2016-12-12 16:00:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Njgxt12-ZBo/beigene-bgne-strong-industry-solid-earnings-estimate-revisions-cm720028,One stock that might be an intriguing choice for investors right now is BeiGene Ltd BGNE This is because this security in the Medical Biomedical Genetics space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective This
BGNE,BGNE:UW,BBG00B6WF8G7,"BeiGene (BGNE): Strong Industry, Solid Earnings Estimate Revisions",2016-12-12 14:09:02 +0000,http://finance.yahoo.com/news/beigene-bgne-strong-industry-solid-140902747.html,"BeiGene (BGNE): Strong Industry, Solid Earnings Estimate Revisions"
BGNE,BGNE:UW,BBG00B6WF8G7,"BeiGene (BGNE): Strong Industry, Solid Earnings Estimate Revisions",2016-12-12 14:09:02 +0000,http://finance.yahoo.com/news/beigene-bgne-strong-industry-solid-140902747.html?.tsrc=rss,"BeiGene (BGNE) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective."
BGNE,BGNE:UW,BBG00B6WF8G7,Should You Buy Beigene Ltd (ADR) (BGNE)?,2016-12-09 18:06:27 +0000,http://finance.yahoo.com/r/04534632-02ab-375a-9955-8e376a6cb57c/should-you-buy-beigene-ltd-adr-bgne-502306?yptr=yahoo&.tsrc=rss,Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
BGNE,BGNE:UW,BBG00B6WF8G7,Should You Buy Beigene Ltd (ADR) (BGNE)?,2016-12-09 18:06:27 +0000,http://www.insidermonkey.com/blog/should-you-buy-beigene-ltd-adr-bgne-502306/,Should You Buy Beigene Ltd (ADR) (BGNE)?
BGNE,BGNE:UW,BBG00B6WF8G7,"Health Care Sector Update for 12/07/2016: CGIX,ANTH,RPRX",2016-12-07 19:15:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6VTl3_QCWA0/health-care-sector-update-for-12072016-cgixanthrprx-cm718210,Top Health Care StocksTop Health Care Stocks JNJ 1 35 JNJ 1 35 PFE 1 79 PFE 1 79 MRK 0 55 MRK 0 55 ABT 0 98 ABT 0 98 AMGN 3 13 AMGN 3 13 Health care stocks were slumping today with the NYSE Health Care Index falling almost 1 0 while shares of health care companies in the S amp
BGNE,BGNE:UW,BBG00B6WF8G7,"Cancer Genetics, Inc. Is Selected by BeiGene, Ltd. to Collaborate on Clinical Trial Services & Advance Portfolio of Novel Oncology Therapeutics",2016-12-07 12:54:07 +0000,http://finance.yahoo.com/news/cancer-genetics-inc-selected-beigene-125407037.html,"[GlobeNewswire] - RUTHERFORD, N.J., Dec. 07, 2016-- Cancer Genetics, Inc., a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced a collaboration with BeiGene, Ltd., a ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-12-06 11:04:05 +0000,http://biz.yahoo.com/e/161206/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 2016 American Society of Hematology Annual Meeting,2016-12-06 03:00:00 +0000,http://finance.yahoo.com/news/beigene-presents-updated-clinical-data-030000951.html,"[GlobeNewswire] - WALTHAM, Mass., Dec. 05, 2016-- BeiGene, Ltd. a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today presented ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia at the 2016 American Society of Hematology Annual Meeting,2016-12-05 16:15:00 +0000,http://finance.yahoo.com/news/beigene-presents-updated-clinical-data-161500714.html,"[GlobeNewswire] - WALTHAM, Mass, Dec. 05, 2016-- BeiGene, Ltd. a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today presented ..."
BGNE,BGNE:UW,BBG00B6WF8G7,[$$] Three Biotechs With Bullish Insider Buying,2016-12-01 11:11:00 +0000,http://www.barrons.com/articles/three-biotechs-with-bullish-insider-buying-1480590696?mod=yahoobarrons&ru=yahoo,[$$] Three Biotechs With Bullish Insider Buying
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Closing of $200 Million Public Offering,2016-11-23 22:36:10 +0000,http://www.publicnow.com/view/A563C47D9DC0FD5B4EBBE13B2763090879597860,"[at noodls] - WALTHAM, Mass., Nov. 23, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment ..."
BGNE,BGNE:UW,BBG00B6WF8G7,5 Stocks Insiders Love Right Now,2016-11-23 19:15:00 +0000,https://www.thestreet.com/story/13904212/1/5-stocks-insiders-love-right-now.html?puc=yahoo&cm_ven=YAHOO,5 Stocks Insiders Love Right Now
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Pricing of $200 Million Public Offering,2016-11-18 01:10:13 +0000,http://www.publicnow.com/view/D26B35589A1642E33F20A606EED6C43DD65B0E59,"[at noodls] - WALTHAM, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Prices Secondary Offering,2016-11-17 15:40:55 +0000,http://finance.yahoo.com/news/beigene-prices-secondary-offering-154055737.html,BeiGene Prices Secondary Offering
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-11-17 11:26:15 +0000,http://biz.yahoo.com/e/161117/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Proposed Public Offering,2016-11-16 22:59:47 +0000,http://finance.yahoo.com/news/beigene-announces-proposed-public-offering-225947988.html,"[GlobeNewswire] - WALTHAM, Mass., Nov. 16, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-11-14 11:17:27 +0000,http://biz.yahoo.com/e/161114/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Lower in Friday Trading,2016-11-11 16:27:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZgIBrU0MEPc/asian-adrs-move-lower-in-friday-trading-cm707817,American depository receipts of Asian stocks were trading 0 38 lower at 140 26 on the Bank of New York Mellon Asia ADR Index on Friday American depository receipts of Asian stocks were trading 0 38 lower at 140 26 on the Bank of New York Mellon Asia ADR Index on Friday In North Asia the
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Updated Clinical Data on PD-1 Antibody BGB-A317 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 31st Annual Meeting,2016-11-11 12:00:00 +0000,http://finance.yahoo.com/news/beigene-presents-updated-clinical-data-120000372.html,"[GlobeNewswire] - WALTHAM, Mass., Nov. 11, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today presented ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene reports 3Q loss,2016-11-11 11:26:51 +0000,http://sg.finance.yahoo.com/news/beigene-reports-3q-loss-112651950.html,BeiGene reports 3Q loss
BGNE,BGNE:UW,BBG00B6WF8G7,Beigene Files for Secondary Offering,2016-11-10 16:15:29 +0000,http://finance.yahoo.com/news/beigene-files-secondary-offering-161529023.html,Beigene Files for Secondary Offering
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Reports Third Quarter 2016 Financial Results,2016-11-10 14:01:04 +0000,http://www.publicnow.com/view/47F145A443D04D3A0D42BD41112F6533A490CC31,"[at noodls] - WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits",2016-11-10 13:59:31 +0000,http://biz.yahoo.com/e/161110/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Oral Presentations on BTK Inhibitor BGB-3111 at the 2016 American Society of Hematology Annual Meeting,2016-11-03 13:00:00 +0000,http://finance.yahoo.com/news/beigene-announces-oral-presentations-btk-130000667.html,"[GlobeNewswire] - WALTHAM, Mass., Nov. 03, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Participate in 25th Annual Credit Suisse Healthcare Conference,2016-11-01 20:15:00 +0000,http://finance.yahoo.com/news/beigene-participate-25th-annual-credit-201500484.html,"[GlobeNewswire] - WALTHAM, Mass., Nov. 01, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Worst Performing Biotech IPOs of 2016,2016-10-10 14:11:00 +0000,http://www.investopedia.com/news/worst-performing-biotech-ipos-2016/?partner=YahooSA,Worst Performing Biotech IPOs of 2016
BGNE,BGNE:UW,BBG00B6WF8G7,"AbbVie and JNJ, BeiGene Presents First Clinical Data for New Cancer Treatment",2016-10-07 21:30:50 +0000,http://finance.yahoo.com/news/beigene-presents-first-clinical-data-213050409.html,"AbbVie and JNJ, BeiGene Presents First Clinical Data for New Cancer Treatment"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Ltd Conference Call on BGB-3111 Data Presentation at IWWM-9 scheduled for 11:00 am ET today,2016-10-07 15:00:00 +0000,http://biz.yahoo.com/cc/2/153942.html,BeiGene Ltd Conference Call on BGB-3111 Data Presentation at IWWM-9 scheduled for 11:00 am ET today
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenstrom’s Macroglobulinemia at 9th International Workshop on Waldenstrom’s Macroglobulinemia,2016-10-07 14:09:06 +0000,http://www.publicnow.com/view/BB5C8F68E8C9F09CA529DBFD033DF71307EC97A9,"[at noodls] - WALTHAM, Mass., Oct. 07, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncological drugs for the ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-10-07 13:52:49 +0000,http://biz.yahoo.com/e/161007/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
BGNE,BGNE:UW,BBG00B6WF8G7,Procter & Gamble and 6 Other Stocks Spiking on Big Volume,2016-10-06 10:08:00 +0000,https://www.thestreet.com/story/13843389/1/procter-amp-gamble-and-6-other-stocks-spiking-on-big-volume.html?puc=yahoo&cm_ven=YAHOO,Procter & Gamble and 6 Other Stocks Spiking on Big Volume
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9,2016-10-04 20:38:05 +0000,http://www.publicnow.com/view/9E495053FD10CFF4C0ED9849F24A81D823C0DE2E,"[at noodls] - WALTHAM, Mass., Oct. 04, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncological drugs for the treatment ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BeiGene Appoints Ross Pettit as Senior Vice President, Global Development Operations",2016-10-03 20:26:03 +0000,http://www.publicnow.com/view/105D0730EA0CD2C22AF9D1D784ADF7CB1196790F,"[at noodls] - WALTHAM, Mass., Oct. 03, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Lower in Thursday Trading,2016-09-29 14:41:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JMGCmAF5j2Q/asian-adrs-move-lower-in-thursday-trading-cm686484,American depository receipts of Asian stocks were trading 0 57 lower at 145 93 on the Bank of New York Mellon Asia ADR Index on Thursday American depository receipts of Asian stocks were trading 0 57 lower at 145 93 on the Bank of New York Mellon Asia ADR Index on Thursday In North Asia
BGNE,BGNE:UW,BBG00B6WF8G7,Coverage initiated on BeiGene by Maxim Group,2016-09-22 09:45:19 +0000,http://finance.yahoo.com/q/ud?s=BGNE,Coverage initiated on BeiGene by Maxim Group
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene (BGNE) Catches Eye: Stock Adds 6% in Session,2016-09-15 14:19:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4diE__oVA_c/beigene-bgne-catches-eye-stock-adds-6-in-session-cm679900,BeiGene Ltd BGNE was a big mover last session as its shares rose a little over 6 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above the volatile price
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene (BGNE) Catches Eye: Stock Adds 6% in Session,2016-09-15 12:25:12 +0000,http://finance.yahoo.com/news/beigene-bgne-catches-eye-stock-122512215.html,BeiGene (BGNE) Catches Eye: Stock Adds 6% in Session
BGNE,BGNE:UW,BBG00B6WF8G7,"Health Care Sector Update for 09/12/2016: BGNE, CUR",2016-09-12 13:50:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AOCeb_2TftE/health-care-sector-update-for-09122016-bgne-cur-cm677823,Top Health care stocks Top Health care stocks JNJ 0 3 JNJ 0 3 PFE 0 6 PFE 0 6 ABT 0 2 ABT 0 2 MRK flatMRK flat AMGN 0 3 AMGN 0 3 Health care shares were mainly lower in pre market trade on Monday Health care shares were mainly lower in pre market trade on Monday
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Receives Approval to Initiate Clinical Trials in China with PD-1 Antibody BGB-A317,2016-09-11 23:18:04 +0000,http://www.publicnow.com/view/16766AF7C6826B94027D7DC9800A0D2E428A5EC6,"[at noodls] - BEIJING, Sept. 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Gets Approval To Initiate Trials In China With PD-1 Antibody BGB-A317,2016-09-11 19:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TVFEcjmSqFk/beigene-gets-approval-to-initiate-trials-in-china-with-pd1-antibody-bgba317-20160911-00022,BeiGene Gets Approval To Initiate Trials In China With PD-1 Antibody BGB-A317
BGNE,BGNE:UW,BBG00B6WF8G7,"BeiGene Appoints Jane Huang, M.D. as Chief Medical Officer, Hematology",2016-09-06 20:29:02 +0000,http://www.publicnow.com/view/76924CD802704F51EE2CCFAE0CB77AEB3FC26636,"[at noodls] - WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ..."
BGNE,BGNE:UW,BBG00B6WF8G7,These 5 Stocks Are Poised for Big Breakouts,2016-09-02 18:26:00 +0000,https://www.thestreet.com/story/13693515/1/these-5-stocks-are-poised-for-big-breakouts.html?puc=yahoo&cm_ven=YAHOO,These 5 Stocks Are Poised for Big Breakouts
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Participate in Baird and Morgan Stanley Global Healthcare Conferences,2016-08-31 20:15:00 +0000,http://finance.yahoo.com/news/beigene-participate-baird-morgan-stanley-201500371.html,"[GlobeNewswire] - WALTHAM, Mass., Aug. 31, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BeiGene Appoints Amy Peterson, M.D. as Chief Medical Officer, Immuno-oncology",2016-08-24 20:38:03 +0000,http://www.publicnow.com/view/A3D06DE5290334C0EF5EBF6487DA8B859B0F95AF,"[at noodls] - WALTHAM, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Receives Approval to Initiate Clinical Trials in China with PARP Inhibitor BGB-290,2016-08-18 12:31:01 +0000,http://www.publicnow.com/view/DA91095D6E32B35082AD3BEEB2E316F850C9A64D,"[at noodls] - WALTHAM, Mass., Aug. 18, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Receives Approval to Initiate Clinical Trials in China with PARP Inhibitor BGB-290,2016-08-18 12:00:00 +0000,http://finance.yahoo.com/news/beigene-receives-approval-initiate-clinical-120000848.html,"[GlobeNewswire] - WALTHAM, Mass., Aug. 18, 2016-- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Reports Second Quarter 2016 Financial Results,2016-08-10 21:41:07 +0000,http://www.publicnow.com/view/3D7DAE319BFCF838D305D37A9BBE8EC899469F08,"[at noodls] - WALTHAM, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits",2016-08-10 20:34:29 +0000,http://biz.yahoo.com/e/160810/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces First Patient Dosing for Investigational BTK Inhibitor BGB-3111 in China,2016-07-05 20:41:04 +0000,http://www.publicnow.com/view/DD56074925077EEB3CE6AAEFF9782148E013582F,"[at noodls] - WALTHAM, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317,2016-06-29 20:51:02 +0000,http://www.publicnow.com/view/7674DB008A59B3A1CD05FB6A8CA0BDAB9F4EA8D5,"[at noodls] - WALTHAM, Mass., June 29, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer, ..."
BGNE,BGNE:UW,BBG00B6WF8G7,U.S. regulator says too many drugmakers chasing same cancer strategy,2016-06-14 20:44:09 +0000,http://finance.yahoo.com/news/u-regulator-says-too-many-204549726.html,U.S. regulator says too many drugmakers chasing same cancer strategy
BGNE,BGNE:UW,BBG00B6WF8G7,Are US IPOs of Chinese companies a safe bet on the first day?,2016-06-10 00:10:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vUBUj5nOqKo/are-us-ipos-of-chinese-companies-a-safe-bet-on-the-first-day-cm633265,"Even as the 2016 IPO market lags the prior year by deal count (34 IPOs 53%), proceeds ($5.5B raised 58%) and filings (49 submissions 54%), US IPO activity of China based companies has kept pace with 2015. Including Thursday's "
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene to Participate in Goldman Sachs 37th Annual Global Healthcare Conference,2016-06-06 12:18:03 +0000,http://www.publicnow.com/view/1A7F3E9EF6342529ECA4FDA80BF144ADA348362B,"[at noodls] - WALTHAM, Mass., June 06, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (Nasdaq:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-06-06 12:07:18 +0000,http://biz.yahoo.com/e/160606/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting,2016-06-05 13:08:06 +0000,http://www.publicnow.com/view/974A52BE438F40CA98D15B89A4AAFC1BE78CAE6F,"[at noodls] - WALTHAM, Mass., June 05, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Hedge Funds’ Favorite Recently-Public Companies amid Atrophied IPO Market,2016-05-26 13:34:32 +0000,http://www.insidermonkey.com/blog/hedge-funds-favorite-recently-public-companies-amid-atrophied-ipo-market-456006/,Hedge Funds’ Favorite Recently-Public Companies amid Atrophied IPO Market
BGNE,BGNE:UW,BBG00B6WF8G7,Biotech-Focused VHCP Management’s Bullish Moves and New Picks,2016-05-24 14:53:43 +0000,http://www.insidermonkey.com/blog/biotech-focused-vhcp-managements-bullish-moves-and-new-picks-455178/,Biotech-Focused VHCP Management’s Bullish Moves and New Picks
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Announces Presentation on BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting,2016-05-19 10:52:06 +0000,http://www.publicnow.com/view/CA873F725A16BC92F8F1153436D25B490F0F0A0E,"[at noodls] - WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 10-Q, Quarterly Report",2016-05-12 20:25:18 +0000,http://biz.yahoo.com/e/160512/bgne10-q.html,"BEIGENE, LTD. Files SEC form 10-Q, Quarterly Report"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Reports First Quarter 2016 Financial Results,2016-05-11 21:07:09 +0000,http://www.publicnow.com/view/36AF54A7FEDC08508315025632C7EAE017767DDA,"[at noodls] - WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BeiGene Appoints Dr. Ji Li as Executive Vice President, Global Head of Business Development",2016-05-04 21:41:02 +0000,http://www.publicnow.com/view/30163991CEC75575A69911E8B8BFDD390668BC70,"[at noodls] - WALTHAM, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) ('BeiGene'), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Change in Directors or Principal Officers",2016-05-04 21:40:24 +0000,http://biz.yahoo.com/e/160504/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Change in Directors or Principal Officers"
BGNE,BGNE:UW,BBG00B6WF8G7,Asian ADRs Move Lower in Wednesday's Trading Session,2016-04-27 15:19:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WRghpBEd3uM/asian-adrs-move-lower-in-wednesdays-trading-session-cm612315,"American depository receipts of Asian stocks were down 0.62% at 135.41 Wednesday morning on the Bank of New York Mellon Asia ADR Index. The decliners in North Asia are led by China Digital TV Holding ( STV ), a"
BGNE,BGNE:UW,BBG00B6WF8G7,"Opening Bell, April 21, 2016",2016-04-21 13:30:00 +0000,http://finance.yahoo.com/video/opening-bell-april-21-2016-133000336.html,"Opening Bell, April 21, 2016"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene (Nasdaq: BGNE) to Ring The Nasdaq Stock Market Opening Bell,2016-04-20 14:21:06 +0000,http://www.publicnow.com/view/14C7A3EFAD47B49C92F5CA2636049002FF5248F9,"[at noodls] - ADVISORY, April 20, 2016 (GLOBE NEWSWIRE) -- What: BeiGene (Nasdaq:BGNE), a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics will visit ..."
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Ltd. :BGNE-US: Earnings Analysis: 2015 By the Numbers,2016-04-19 13:26:25 +0000,http://www.capitalcube.com/blog/index.php/beigene-ltd-bgne-us-earnings-analysis-2015-by-the-numbers/,BeiGene Ltd. :BGNE-US: Earnings Analysis: 2015 By the Numbers
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Presents Clinical Data for RAF Dimer Inhibitor BGB-283 at the 2016 American Association for Cancer Research Annual Meeting,2016-04-17 21:26:56 +0000,http://www.publicnow.com/view/3FDE22EE077CE2DB7A9F2136A5557F626437225E,"[at noodls] - WALTHAM, Mass., April 17, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) ('BeiGene'), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BeiGene Appoints Eric Hedrick, M.D. as Interim Chief Medical Officer",2016-04-11 21:11:22 +0000,http://www.publicnow.com/view/552070FD75B054D6D573B36F2EC99783213CB2D3,"[at noodls] - WALTHAM, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) ('BeiGene'), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology ..."
BGNE,BGNE:UW,BBG00B6WF8G7,"BEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati",2016-04-11 21:10:27 +0000,http://biz.yahoo.com/e/160411/bgne8-k.html,"BEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati"
BGNE,BGNE:UW,BBG00B6WF8G7,Renaissance Capital's 1Q16 US IPO Market Review,2016-04-01 22:28:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nVgjwiVumJY/renaissance-capitals-1q16-us-ipo-market-review-cm598858,"The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008 2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7"
BGNE,BGNE:UW,BBG00B6WF8G7,BeiGene Reports Fourth Quarter and Full Year 2015 Financial Results,2016-03-30 20:31:20 +0000,http://www.publicnow.com/view/772AFBF0692CEB8479FA24A909149FD8E8F959EA,"[at noodls] - WALTHAM, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) ('BeiGene'), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology ..."
BGNE,BGNE:UW,BBG00B6WF8G7,Week ahead: IPO calendar fills up,2016-03-14 15:39:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uR5Zr6uA4wU/week-ahead-ipo-calendar-fills-up-cm592316,"After seeing just one IPO price in the past month, and five this year, there are three IPOs on the calendar next week.  The increased activity comes on the heels of IPO index outperformance. Since the February 11 lows, the"
BGNE,BGNE:UW,BBG00B6WF8G7,First two IPOs of 2016 trade up; IPO market continues its 3-year biotech run,2016-02-16 09:52:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xWxbio4MxW0/first-two-ipos-of-2016-trade-up-ipo-market-continues-its-3-year-biotech-run-cm574586,"The IPO market continues its three year run of biotech offerings. The Nasdaq Biotech Index is down 23% this year. A whopping 81% of 2015 biotech IPOs trade below issue. Against that backdrop, large biotechs Editas Medicine ( EDIT"
BGNE,BGNE:UW,BBG00B6WF8G7,Biotechs lean heavily on insider buying to complete quasi-IPOs,2016-02-12 17:47:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5ffWpYTO77I/biotechs-lean-heavily-on-insider-buying-to-complete-quasi-ipos-cm578796,"Accounting for 100% of the four IPOs so far this year, biotechs appeared to be the one sector able to generate demand from public investors. But demand is weaker than it seems. Of the nearly $400 million raised, insiders"
BGNE,BGNE:UW,BBG00B6WF8G7,US IPO Weekly Recap: Two big biotechs break the ice as the first IPOs of 2016 trade up,2016-02-06 01:13:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XY4SovZPUyk/us-ipo-weekly-recap-two-big-biotechs-break-the-ice-as-the-first-ipos-of-2016-trade-up-cm575838,"Two large biotechs traded up as the first IPOs of 2016. As we noted in our mid week blog post , both biotechs went public in a challenging market The Nasdaq biotech Index is down 25% this year and"
BGNE,BGNE:UW,BBG00B6WF8G7,"Chinese cancer biotech BeiGene prices IPO at $24, the high end of the range",2016-02-03 16:13:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wWHuaCf69t4/chinese-cancer-biotech-beigene-prices-ipo-at-24-the-high-end-of-the-range-cm574132,"BeiGene, a Chinese biotech developing cancer therapies for China and global markets, raised $158 million by offering 6.6 million shares at $24, the high end of the range of $22 to $24. BeiGene plans to list on the Nasdaq"
BGNE,BGNE:UW,BBG00B6WF8G7,Week ahead: Biotechs could snap IPO drought,2016-02-01 17:13:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KwaFi7eF-wU/week-ahead-biotechs-could-snap-ipo-drought-cm572443,"February is kicking off with four potential biotech pricings, including heavy hitters Editas Medicine and BeiGene. These two IPOs could breathe life back into the IPO market after a deal less January and the Nasdaq Biotech Index, which is"
BGNE,BGNE:UW,BBG00B6WF8G7,Chinese immunotherapy biotech BeiGene sets terms for $127 million IPO,2016-01-20 00:20:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/52pVvRoV5is/chinese-immunotherapy-biotech-beigene-sets-terms-for-127-million-ipo-cm567697,"BeiGene, a Chinese biotech developing immunotherapies based on kinase inhibitors, announced terms for its IPO on Tuesday. The Beijing, China based company plans to raise $126.5 million by offering 5.5 million ADSs at a price range of $22 to"
